CRL

296.41

0.44% 1.31

시간 외 거래: 296.41

Charles River Laboratories International Inc (CRL)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측

전일 마감가:

$295.10

열려 있는:

$297.01

하루 거래량:

901.31K

Relative Volume:

1.00

시가총액:

$14.15B

수익:

$4.03B

순이익/손실:

$-182.84M

주가수익비율:

-78.83

EPS:

-3.7603

순현금흐름:

$391.29M

1주 성능:

+1.70%

1개월 성능:

+32.15%

6개월 성능:

+66.07%

1년 성능:

+82.07%

1일 변동 폭

$295.93

$303.31

1주일 범위

$289.07

$303.31

52주 변동 폭

$144.26

$303.31

Charles River Laboratories International Inc Stock (CRL) Company Profile

명칭

Charles River Laboratories International Inc

부문

Healthcare (1082)

산업

Diagnostics & Research (50)

전화

781-222-6000

주소

251 BALLARDVALE ST, WILMINGTON, MA

직원

19,700

트위터

@criverlabs

다음 수익 날짜

2026-08-05

최신 SEC 제출 서류

CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, NTRA, A, IQV

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CRL Charles River Laboratories International Inc	296.41	13.91B	4.03B	-182.84M	391.29M	-3.7603
TMO Thermo Fisher Scientific Inc	630.70	232.03B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	215.68	151.78B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	338.70	46.82B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	157.69	44.14B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	262.38	42.15B	16.63B	1.39B	2.12B	8.0674

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-06-17	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2026-05-29	업그레이드	CLSA	Hold → Outperform
2026-04-14	개시	RBC Capital Mkts	Outperform
2025-12-15	업그레이드	BofA Securities	Neutral → Buy
2025-11-17	업그레이드	Argus	Hold → Buy
2025-11-06	업그레이드	Robert W. Baird	Neutral → Outperform
2025-10-06	업그레이드	William Blair	Mkt Perform → Outperform
2025-10-02	업그레이드	Barclays	Equal Weight → Overweight
2025-09-09	업그레이드	Jefferies	Hold → Buy
2025-07-09	업그레이드	Citigroup	Neutral → Buy
2025-05-23	업그레이드	Redburn Atlantic	Neutral → Buy
2025-05-14	업그레이드	TD Cowen	Hold → Buy
2025-05-08	업그레이드	Evercore ISI	In-line → Outperform
2025-03-21	다운그레이드	Goldman	Buy → Neutral
2025-03-04	업그레이드	Citigroup	Sell → Neutral
2025-03-03	업그레이드	Redburn Atlantic	Sell → Neutral
2025-01-22	다운그레이드	William Blair	Outperform → Mkt Perform
2025-01-17	다운그레이드	UBS	Buy → Neutral
2024-11-18	다운그레이드	CLSA	Hold → Underperform
2024-11-07	업그레이드	CLSA	Underperform → Hold
2024-10-23	개시	CLSA	Underperform
2024-10-14	개시	Redburn Atlantic	Sell
2024-10-07	다운그레이드	Evercore ISI	Outperform → In-line
2024-10-02	다운그레이드	BofA Securities	Buy → Neutral
2024-10-01	다운그레이드	Citigroup	Neutral → Sell
2024-08-08	다운그레이드	JP Morgan	Overweight → Neutral
2024-08-08	다운그레이드	Robert W. Baird	Outperform → Neutral
2024-06-28	다운그레이드	Argus	Buy → Hold
2024-06-07	개시	Mizuho	Neutral
2024-06-06	개시	Goldman	Buy
2024-02-15	다운그레이드	Guggenheim	Buy → Neutral
2023-09-13	개시	TD Cowen	Market Perform
2023-07-10	다운그레이드	Citigroup	Buy → Neutral
2023-02-23	업그레이드	Guggenheim	Neutral → Buy
2023-01-12	다운그레이드	Jefferies	Buy → Hold
2022-09-30	업그레이드	Jefferies	Hold → Buy
2022-08-25	개시	Credit Suisse	Outperform
2022-08-04	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2022-05-24	개시	Guggenheim	Neutral
2022-04-25	다운그레이드	Jefferies	Buy → Hold
2022-04-07	개시	Stephens	Overweight
2022-02-17	재확인	BofA Securities	Buy
2022-02-17	업그레이드	Citigroup	Neutral → Buy
2022-02-17	재확인	Deutsche Bank	Buy
2022-02-17	재확인	Morgan Stanley	Overweight
2022-02-17	재확인	UBS	Buy
2021-08-05	재개	Credit Suisse	Neutral
2020-12-16	다운그레이드	Citigroup	Buy → Neutral
2020-09-10	업그레이드	Jefferies	Hold → Buy
2020-07-01	업그레이드	BofA Securities	Neutral → Buy
2020-05-13	업그레이드	UBS	Neutral → Buy
2020-04-21	다운그레이드	Jefferies	Buy → Hold
2020-03-27	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2020-03-02	개시	Deutsche Bank	Buy
2020-02-18	업그레이드	Wolfe Research	Peer Perform → Outperform
2020-01-10	업그레이드	Goldman	Neutral → Buy
2020-01-08	개시	Wells Fargo	Overweight
2020-01-07	개시	Citigroup	Buy
2019-10-18	다운그레이드	BofA/Merrill	Buy → Neutral
2019-06-10	개시	SVB Leerink	Outperform
2019-04-30	재개	Evercore ISI	Outperform
2018-12-14	개시	Deutsche Bank	Buy
2018-10-09	개시	UBS	Neutral
2018-08-23	업그레이드	Raymond James	Mkt Perform → Outperform
2018-07-17	업그레이드	RBC Capital Mkts	Sector Perform → Outperform
2018-06-15	업그레이드	KeyBanc Capital Mkts	Sector Weight → Overweight
2018-02-14	업그레이드	SunTrust	Hold → Buy

모두보기

Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스

Aug 21, 2026

What Does Charles River Laboratories International (CRL) Gain From This Vaccine Collaboration? - simplywall.st

Aug 21, 2026

Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development? - Yahoo Finance

Aug 21, 2026

CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running? - TradingView

Aug 21, 2026

Charles River Labs stock holds near fresh 52-week high after strong Q2 earnings - Ad-hoc-news.de

Aug 21, 2026

Are Options Traders Betting on a Big Move in Charles River Stock? - TradingView

Aug 21, 2026

Charles River Gains 88.6% in a Year: What's Driving the Rally? - Yahoo Finance

Aug 21, 2026

Madison Asset Management LLC Invests $3.81 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat

Aug 21, 2026

Aug 20, 2026

Charles River Labs CEO Birgit Girshick Gifts 528 Shares, Retains Significant Ownership - Kalkine Media

Aug 20, 2026

Charles River Laboratories Director Nancy C. Andrews Reports Form 4 Filing on Stock Option Exercise and Sale - Kalkine Media

Aug 20, 2026

Charles River Labs CEVP Parisotto sells $599,710 in shares By Investing.com - Investing.com Australia

Aug 20, 2026

Charles River Laboratories International (NYSE:CRL) Director Nancy Andrews Sells 573 Shares - MarketBeat

Aug 20, 2026

Charles River (NYSE: CRL) CEO makes 528-share gift of common stock - Stock Titan

Aug 20, 2026

Shannon Parisotto Sells 2,039 Shares of Charles River Laboratories International (NYSE:CRL) Stock - MarketBeat

Aug 20, 2026

Charles River Labs CEVP Parisotto sells $599,710 in shares - Investing.com

Aug 20, 2026

Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing - marketscreener.com

Aug 20, 2026

Charles River (NYSE: CRL) insider sells 2,039 shares in 10b5-1 plan - Stock Titan

Aug 20, 2026

Charles River (NYSE: CRL) director exercises options, sells 573 shares - Stock Titan

Aug 20, 2026

Charles River Labs stock hits fresh 52-week high as Medigen vaccine deal boosts sentiment - Ad-hoc-news.de

Aug 20, 2026

Charles River Laboratories stock hits 52-week high at $294.68 By Investing.com - Investing.com Nigeria

Aug 20, 2026

Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing - BioSpace

Aug 20, 2026

Charles River Laboratories International, Inc. and Medigen Vaccine Biologics Corp. Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing - marketscreener.com

Aug 20, 2026

MEX:CRL EV-to-OCF: 27.30 — 36% Above Median - GuruFocus

Aug 20, 2026

Aug 19, 2026

Is Charles River Laboratories International Inc (CRL) Overvalued - GuruFocus

Aug 19, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Aug 19, 2026

Charles River (NYSE: CRL) officer to sell 2,039 shares after option exercise - Stock Titan

Aug 19, 2026

Charles (CRL) Snapshot: Moves 4.77% Up to $292.52 in the Latest Session; Levels: the $277.89 to $307.15 Range Remains in FocusMotive Wave - Vinanet

Aug 19, 2026

Charles (CRL) Results Versus Estimates: Profit Per Share Surpasses Its Benchmark at the Close; Trading Move - Vinanet

Aug 19, 2026

Charles River Laboratories International (CRL) Cut 2026 Guidance, Is The Stock Still 11% Undervalued? - simplywall.st

Aug 19, 2026

Aug 18, 2026

Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Aug 18, 2026

Charles River Labs stock reaches new 12-month high as 2026 guidance lifts expectations - Ad-hoc-news.de

Aug 18, 2026

Charles River (NYSE: CRL) investor to sell 573 shares via UBS - Stock Titan

Aug 18, 2026

Aug 17, 2026

Resilient Charles River Labs stock hits new 12-month high as Q2 revenue tops $1 billion - AD HOC NEWS

Aug 17, 2026

Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month HighHere's Why - MarketBeat

Aug 17, 2026

Birgit Girshick maps out Charles River's post-divestiture future: re-accelerating growth and a lighter portfolio - The Pharma Letter

Aug 17, 2026

Aug 16, 2026

CRL Q2 2026 Earnings: EPS Surge of 9.23% Beats Estimates as Shares Nudge LowerEarnings Volatility Report - Vinanet

Aug 16, 2026

What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing? - Moomoo

Aug 16, 2026

Aug 15, 2026

Handelsbanken Fonder AB Increases Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat

Aug 15, 2026

Aug 14, 2026

Lowered 2026 EPS Outlook and Rebounding Demand Could Be A Game Changer For Charles River (CRL) - simplywall.st

Aug 14, 2026

If You Invested $100 In Charles River Stock 15 Years Ago, You Would Have This Much Today - Benzinga

Aug 14, 2026

Aug 13, 2026

Birgit Girshick Sells 6,500 Shares of Charles River Laboratories International (NYSE:CRL) Stock - MarketBeat

Aug 13, 2026

Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Aug 13, 2026

Charles River Labs (CRL) CEO exercises 6,500 options and sells shares under 10b5-1 plan - Stock Titan

Aug 13, 2026

Charles River (CRL) executive Parisotto exercises options, sells 3,714 shares under 10b5-1 plan - Stock Titan

Aug 13, 2026

Invesco reports 2.98M-share stake in Charles River Laboratories (CRL) - Stock Titan

Aug 13, 2026

Aug 12, 2026

Charles River Laboratories stock hits 52-week high at $285.13 - Investing.com

Aug 12, 2026

Charles River Laboratories stock hits 52-week high at $285.13 By Investing.com - Investing.com Australia

Aug 12, 2026

Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 12, 2026